Recombinant mutant human tumor necrosis factor-α derivative
重组人肿瘤坏死因子α衍生物3a
Report date: 2022/01/14 13:23:58
Base Information
Drug NameRecombinant mutant human tumor necrosis factor-α derivative
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPending (NDA/BLA)
Highest Status in ChinaPending
Originator CompaniesShanghai Angli Fanlong Bioengineering Research Institute Co LtdSph Changzhou Pharmaceutical Co LtdSecond Military Medical University Of Chinese People'S Liberation Army
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesN/A
Inactive CompaniesSecond Military Medical University Of Chinese People'S Liberation ArmyShanghai Angli Fanlong Bioengineering Research Institute Co LtdSph Changzhou Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A